CervoMed Inc. (CRVO)
| Bid | 2.11 |
| Market Cap | 18.03M |
| Revenue (ttm) | 7.71M |
| Net Income (ttm) | -11.33M |
| EPS (ttm) | -2.17 |
| PE Ratio (ttm) | -1.01 |
| Forward PE | -1.22 |
| Analyst | Buy |
| Ask | 2.3 |
| Volume | 32,675 |
| Avg. Volume (20D) | 435,388 |
| Open | 2.15 |
| Previous Close | 2.18 |
| Day's Range | 2.14 - 2.26 |
| 52-Week Range | 1.80 - 26.38 |
| Beta | 1.83 |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts....
Analyst Forecast
According to 8 analyst ratings, the average rating for CRVO stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 1501.83% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · marketwatch.com
CervoMed's stock craters 77% after failed trial of treatment for rare brain diseaseCervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
